FY23 consensus $2.65. Backs FY23 revenue view to $825M-$845M, consensus $835.91M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on HALO:
- HALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTS
- Acumen, Halozyme enter global collaboration, license agreement
- Halozyme enters non-exclusive license agreement with Acumen Pharmaceuticals
- HALO Upcoming Earnings Report: What to Expect?
- Halozyme confirms ‘positive’ results from Bristol Myers’ Phase 3 CheckMate-67T
